{"entity":{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","aka":[],"tldr":"Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.","summary":"Ross Camidge led the first crizotinib expansion cohort in ALK-positive lung cancer and was principal investigator of the ALTA and ALTA-1L brigatinib trials, and senior author on ALEX (alectinib). He has championed CNS-specific endpoints and ctDNA monitoring in oncogene-driven disease. He directs thoracic oncology research at the University of Colorado.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Camidge%20DR%5BAuthor%5D%20ALK%20lung"}],"tags":["lung","alk","targeted-therapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["alk"],"drugs":["lorlatinib"],"companies":[],"institutions":["colorado-cancer-center"],"pathways":[],"terms":[],"trials":["crown"],"people":[],"bottlenecks":[],"keyPapers":["paper-shaw-crown-lorlatinib-crizotinib-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center","institutionId":"colorado-cancer-center","specialisms":["ALK-positive lung cancer","Oncogene-driven NSCLC","Brain metastases","Trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Camidge%20DR%5BAuthor%5D%20ALK%20lung"}],"papers":[{"title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (ALEX)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1704795"},{"title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1810171"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"}]},"route":"/people/ross-camidge/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"}],"drug":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"}],"institution":[{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/"}],"trial":[{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/"},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/"},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/"},{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/"}],"paper":[{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/"},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/"}]}}